INDUSTRY NEWS
On September 9, China’s National Health Commission (NHC), Ministry of Industry and Information Technology (MIIT), National Healthcare Security A…
To acquire China National Medical Products Administration (NMPA)’s marketing authorization for medical devices, companies need to file or register the…
On Mar. 3, 2023, China Center for Drug Evaluation (CDE) released six Q&As on drug master file (DMF) filing (Q&A No. 1-2) and drug application’…
On Jan. 1, 2023, China National Medical Products Administration (NMPA) started to require that all documents for drug registration applications, as we…
After consulting on the draft in Nov. 2022, China National Medical Products Administration (NMPA) released the Administrative Rules on Supervising Dru…
On May 13, 2021, China National Medical Products Administration (NMPA) released the Good Pharmacovigilance Practices (GVP), which has been effective s…
On Jan. 11, 2023, China Center for Drug Evaluation (CDE) released 10 Q&As, including nine questions on the electronic submission of drug applicati…
In July 2018, China optimized the clinical trial applications (CTA) / investigational new drug (IND) applications’ review and approval procedure…
This is a collection of China’s recent pharmaceutical laws, regulations, policies, and standards, mainly issued by the following authorities: National…